Medical Condition News

RSS

Combination treatment strategies may benefit patients with non-small cell lung cancer

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell.

20 Jan 2010

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Oramed Pharmaceuticals Inc. announced today the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801.

20 Jan 2010

New analysis reveals high rates of CNS disorders in autistic children

Nearly two-thirds of the children with Autistic Spectrum Disorders recorded in the National Birth Defect Registry (NBDR) also suffer from structural birth defects, according the national nonprofit, Birth Defect Research for Children (BDRC).

20 Jan 2010

New research at Rhode Island Hospital identifies a treatment for glioblastomas

New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.

20 Jan 2010

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

20 Jan 2010

Study shows an intriguing relationship between cancer-related genes and schizophrenia susceptibility

People who inherit a specific form of a gene that puts them on a road to schizophrenia may be protected against some forms of cancer, according to a new study by scientists at The Feinstein Institute for Medical Research.

20 Jan 2010

Researchers propose a new model for breast cell differentiation

A study by researchers at Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts Medical Center improves our current understanding of the origins of breast cancer. The

19 Jan 2010

Repeated exposure to tobacco smoke makes lung cancer much worse

Repeated exposure to tobacco smoke makes lung cancer much worse, and one reason is that it steps up inflammation in the lung. Scientists at the University of California, San Diego School of Medicine have found that mice with early lung cancer lesions that were repeatedly exposed to tobacco smoke developed larger tumors - and developed tumors more quickly - than unexposed animals.

19 Jan 2010

A novel approach for funding children's genetic disease research

Parent Project Muscular Dystrophy together with Trisomy 18 Foundation are among 100 charities that earned a $25,000 grant during Round 1 of the Chase Community Giving Challenge on Facebook.

19 Jan 2010

Social factors still influence access to cancer services

People who develop the most common forms of cancer are still more likely to be diagnosed at a late stage in their disease if they live in a deprived area, new research has found.

19 Jan 2010

Corventis' NUVANT MCT System for detecting non-lethal arrhythmias receives FDA marketing clearance

Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.

19 Jan 2010

Leafy green vegetables, folate and multivitamins can prevent lung cancer in smokers

Leafy green vegetables, folate, and some multivitamins could serve as protective factors against lung cancer in current and former smokers, according to a study that is a first step in understanding a complex association.

19 Jan 2010

DURECT commences dosing in its POSIDUR Phase III clinical trial

DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.

19 Jan 2010

GenVec and Novartis collaborate to develop novel treatments for hearing loss and balance disorders

GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec's innovative adenovector technology may have the potential to restore hearing and balance function.

19 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

PCI Biotech AS completes second dose group in phase I/II study of Amphinex

PCI Biotech AS ( PCIB.OL) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.

19 Jan 2010

Gastric bypass surgery may increase life expectancy of morbidly obese individuals

A computerized model suggests that most morbidly obese individuals would likely live longer if they had gastric bypass surgery, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals. However, the best decision for individual patients varies based on factors such as age, increasing body mass index and the effectiveness of surgery.

19 Jan 2010

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

19 Jan 2010

HDL launches new preventative model to help physicians manage chronic diseases

Health Diagnostic Laboratory Inc. (HDL), www.hdlabinc.com, announced today the launch of its new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions.

19 Jan 2010

Learning Lab of Brentwood conducts a series of monthly presentations on ADHD

Are you concerned that your child has ADHD? Maybe you're not sure exactly what the signs are. Perhaps you are against medicating your child. According to the American Academy of Pediatrics, "ADHD is the most commonly diagnosed behavioral condition in children, affecting approximately 6% to 9% of the school-aged population.

19 Jan 2010

Medical Condition News

Combination treatment strategies may benefit patients with non-small cell lung cancer

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

New analysis reveals high rates of CNS disorders in autistic children

New research at Rhode Island Hospital identifies a treatment for glioblastomas

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Study shows an intriguing relationship between cancer-related genes and schizophrenia susceptibility

Researchers propose a new model for breast cell differentiation

Repeated exposure to tobacco smoke makes lung cancer much worse

A novel approach for funding children's genetic disease research

Social factors still influence access to cancer services

Corventis' NUVANT MCT System for detecting non-lethal arrhythmias receives FDA marketing clearance

Leafy green vegetables, folate and multivitamins can prevent lung cancer in smokers

DURECT commences dosing in its POSIDUR Phase III clinical trial

GenVec and Novartis collaborate to develop novel treatments for hearing loss and balance disorders

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

PCI Biotech AS completes second dose group in phase I/II study of Amphinex

Gastric bypass surgery may increase life expectancy of morbidly obese individuals

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

HDL launches new preventative model to help physicians manage chronic diseases

Learning Lab of Brentwood conducts a series of monthly presentations on ADHD

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News